Free Trial
EPA:DIM

Sartorius Stedim Biotech (DIM) Stock Price, News & Analysis

Sartorius Stedim Biotech logo
€204.40 -4.20 (-2.01%)
As of 02/21/2025

About Sartorius Stedim Biotech Stock (EPA:DIM)

Key Stats

Today's Range
€202.90
€209.10
50-Day Range
€181.20
€225.50
52-Week Range
N/A
Volume
86,865 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.

Receive DIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sartorius Stedim Biotech and its competitors with MarketBeat's FREE daily newsletter.

DIM Stock News Headlines

RBC Capital Sticks to Its Buy Rating for Sartorius Stedim Biotech (0RG8)
Sartorius Stedim Biotech releases Universal Registration Document 2024
Nvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."
If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk’s new technology could help launch an entirely new multitrillion-dollar industry.
Sartorius Stedim Biotech Preliminary FY24 Profit Declines - Quick Facts
Sartorius Stock: JPMorgan Boost Drives 4% Market Surge
RBC Capital Sticks to Its Hold Rating for Sartorius (0NIR)
See More Headlines

DIM Stock Analysis - Frequently Asked Questions

Sartorius Stedim Biotech's stock was trading at €188.70 at the beginning of 2025. Since then, DIM stock has increased by 8.3% and is now trading at €204.40.
View the best growth stocks for 2025 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sartorius Stedim Biotech investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Corbus Pharmaceuticals (CRBP), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX) and C3.ai (AI).

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Instruments & Supplies
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
10,493
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (EPA:DIM) was last updated on 2/22/2025 by MarketBeat.com Staff
From Our Partners